Orexo is a fully integrated specialty pharmaceutical company
Opioid addiction is a treatable chronic disease
Developed 4 products approved worldwide
Embracing all aspects of opioid addiction
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
Listen to an interview (shortened version) with CEO, Nikolaj Sorensen, where he shares his experiences that have sh… https://t.co/dLu3kvBMwk
Lyssna på en längre intervju med #Orexo s VD Nikolaj Sørensen där han delar med sig av sina tidigare erfarenheter s… https://t.co/ki5QLhqLT3
INNOVATION IS THE HEART OF WHAT WE DO - #Orexo is built on the principle of innovation which remains at the core of… https://t.co/yKnzgAVuPI
When you sign up to our newsletter or press releases, we use the data necessary for this purpose, or the data separately provided by you, to send you our email regularly. You can unsubscribe from our newsletter or press releases at any time via a link provided in the email.